Amarin Corp Plc (AMRN)

[ggwpq]

The BIP study is listed in Amarin Sept's presentation (p.10). Here is the link for the BIP study,

http://circ.ahajournals.org/content/102/1/21.long

" Among patients with baseline triglycerides ≥200 mg/dL (225 patients in the placebo group and 234 in the bezafibrate group), bezafibrate reduced the cumulative probability of a primary end point by 39.5% (P=0.02), "

"Although the overall effect of bezafibrate on the incidence of primary end points was moderate (P=0.24), the reduction in the primary end point was impressive in the subgroup of patients with high baseline triglycerides (≥200 mg/dL)."

One should go thru all studies mentioned, time permitting, on that p.10 to confirm or deny R-IT's chance of success.

I am puzzled that there is no stand alone US/EU trig. trial ever. Please let me know if you find any.